


REMARKS/ARGUMENTS

Applicants are required to elect a single species.

Applicants elect the species of Example 1, i.e., the compound (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride.

Regarding the variables of formula I, the elected compound is where R_1 is CH_3 , R_2 is R'_2 , more specifically $-O-X_1$, more specifically wherein X_1 is C_{3-8} alkyl substituted by 1 to 17 fluorine atoms, more specifically



R_3 is $-CH_3$ OH, R_4 is H and R_5 is H.

The election is made with traverse. It is stated that the compound of applicants' claims do not contain a common core. This is clearly incorrect because all of the compounds contain the common core of formula I, i.e., a propanol moiety bonded to a nitrogen atom at one end and a substituted phenyl moiety at the other end.


It is noted that upon allowance of a generic claim, applicants will be entitled to consideration of claims to additional species.

The pending claims encompassing the invention are claims 1-4 and 7-10.

This communication is believed to be fully responsive to the Office Action. Action on the merits is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: 23 February 2007